# Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)

Source: https://onco.cc/trials/nct06031246/  
OnCo record `nct06031246` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Fudan University, now recruiting.

## Summary

Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) is a phase 3, interventional study registered as NCT06031246 by Fudan University, with a registry enrolment figure of 634 participants, started 2023-04-01 and due to reach its primary completion in 2026-01-01. Interventions recorded: Selective Lymph Node Dissection. Conditions listed: Lung Adenocarcinoma; Lymph Node Metastasis. Primary outcome: 5-year overall survival. Lung eligibility wording from the registry: "Not receiving lung cancer surgery before;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06031246
- Phase: 3
- Setting: Selective Lymph Node Dissection for cT1N0M0 Invasive Non-small Cell Lung Cancer With CTR>0.5 Located in the Apical Segment: a Single-arm, Multi-center, Phase III Trial
- Sponsor: Fudan University
- Enrolled: 634

## Sources

- ClinicalTrials.gov NCT06031246: https://clinicaltrials.gov/study/NCT06031246

## Connected records

- cancers: [Adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06031246.json